Gonorrhea resistance testing could pay for itself as ceftriaxone resistance rises

Modeling published in PLOS Medicine examined a practical question with immediate relevance for sexual health clinics: when does reflex resistance testing for Neisseria gonorrhoeae become worth the expense? The analysis focused on whether testing strategies that identify antimicrobial resistance before treatment can reduce overall healthcare costs by steering patients toward the right drug sooner, avoiding treatment failure, repeat visits, and downstream complications.

The answer depended heavily on the local resistance environment. Where ceftriaxone resistance remained absent or rare, the added cost of resistance testing was harder to justify. As resistance prevalence climbed, the economics shifted quickly, because every incorrect empiric choice carried a larger price tag in repeat care and persistent infection.

This is not a theoretical problem. Gonorrhea treatment has always been tied to the fragility of the antibiotic pipeline, and a single missed resistance profile can ripple through index cases, partners, and follow-up care.

A simulated clinic pathway with repeat visits and partner treatment

The model followed a simplified patient pathway from clinic presentation through gonorrhea testing, treatment selection, cure, persistent infection, or loss to follow-up. Symptomatic patients with persistent infection could return for repeat testing, which mirrors what happens in real care when first-line treatment fails or symptoms do not resolve. The partner treatment module added another layer of realism: partners of truly infected index cases were assigned a probability of infection, creating a pathway for ongoing transmission and additional treatment costs.

This structure matters because gonorrhea control is rarely limited to the first encounter. Each untreated or undertreated infection can generate secondary cases, and partner management can become a major driver of resource use. In that sense, the model did not simply ask whether a resistance test changes the initial prescription. It asked whether better matching therapy to resistance patterns can reduce total system burden across an entire care cascade.

Cost pressure rose as resistance patterns worsened

Across the modeled scenarios, average per-person gonorrhea care costs increased when ceftriaxone resistance was more common, especially in the setting of no resistance testing. The figures separated cost by category and by population group, including men who have sex with men, men who have sex with women, and women. They also distinguished index-case complications from partner-related costs, which is important because partner treatment can be a hidden source of expense even when the original patient is cured.

One striking feature of the results is that the cost burden was not flat across groups or resistance assumptions. The model showed that ceftriaxone resistance changed the economic balance much more sharply than ciprofloxacin resistance alone, because ceftriaxone remains central to contemporary gonorrhea treatment decisions. Once a higher share of infections is no longer susceptible to the standard regimen, empiric treatment becomes a gamble with real downstream costs.

When resistance testing was layered into the pathway, mean per-person costs shifted again. Ciprofloxacin-only testing and combined ciprofloxacin-plus-ceftriaxone testing reduced the likelihood of inefficient treatment under the relevant resistance scenarios, and the gains were greatest where ceftriaxone resistance was present. In practical terms, the test becomes more valuable as the probability of wrong therapy rises.

The price ceiling for testing depended on resistance prevalence

The analysis also estimated the cost-neutral threshold price for reflex resistance testing. In other words, it calculated the maximum price a test could carry without increasing total healthcare spending. Those thresholds were shown for single-target strategies and for multi-target strategies, and they varied by the prevalence of novel drug A resistance as well as ceftriaxone resistance.

That price ceiling is the key operational metric for laboratory and procurement decisions. If a resistance assay costs less than the threshold, the health system can use it without increasing total spend, at least under the model’s assumptions. If it costs more, the system pays a premium for information that may still be clinically useful but no longer budget-neutral.

For men who have sex with men, Table 2 went further and estimated the per-test value of a single-target resistance test and a triple-target resistance test under a specific resistance scenario: 50% ciprofloxacin resistance, 5% ceftriaxone resistance, and 0% resistance to novel drug A. That is the kind of granular output clinicians and payers need when they are deciding whether a more sophisticated assay is worth deploying in a high-prevalence setting.

Why the biology and the economics point in the same direction

Gonorrhea resistance testing works because it compresses uncertainty before treatment. Instead of assuming susceptibility and discovering failure later, clinicians can use resistance information to steer therapy away from ineffective agents. In a pathogen where resistance can spread quickly and treatment options are limited, that single step can prevent repeat infections, reduce persistent symptoms, and lower the chance of further transmission to partners.

The cost model reflects that biology. If the probability of ceftriaxone resistance is low, empiric treatment still performs reasonably well and the incremental value of testing is smaller. Once resistant strains become more common, the model rewards earlier identification because avoided failures accumulate across the pathway: fewer repeat consultations, fewer ongoing symptoms, less partner treatment, and fewer complication-related costs.

The scenario for novel drug A is also important. The figures show how the appearance of resistance to a newer therapeutic option changes the economics again, because every added resistance target reduces the safety margin for empiric care. As the arsenal narrows, the value of precise microbiologic guidance increases.

What this means for sexual health services

The main implication is straightforward: reflex resistance testing is most compelling in settings where ceftriaxone resistance is already present or likely to emerge. In lower-resistance settings, the test may still offer clinical benefits, but the budget case is weaker. In higher-resistance settings, the calculus changes quickly, and a test that looks expensive in isolation may prevent even larger treatment and follow-up costs.

For clinicians, this argues for local resistance surveillance to guide testing policy rather than a one-size-fits-all approach. For health systems, it argues for thinking about resistance assays as part of the treatment pathway, not as an optional laboratory add-on.

The model’s limitations are the usual ones for simulation work: its conclusions depend on assumed parameter values, the prevalence scenarios examined, and the structure of the care pathway built into the analysis. Even so, the direction of travel is hard to miss. As gonorrhea resistance increases, the economic argument for resistance-guided treatment strengthens, and the threshold for a cost-neutral test becomes easier to meet.


Reporting by Dr. A.R. Athira, MBBS for Medicine World Foundation, with additional data provided by PLOS Medicine.
PRIMARY CLINICAL EVIDENCE & REGISTRY DATA